［1］Dongsheng Y，Shidong X，Qun W，et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage ⅢA EGFR mutation-positive non-small-cell lung cancer（EVAN）：a randomised，open-label，phase 2 trial［J］. The Lancet Respiratory Medicine，2018，6：863-873.

［2］Wang Y N，Yao S，Wang C L，et al. Clinical significance of 4L lymph node dissection in left lung cancer.Journal of clinical oncology，2018，36（29）：2935-2942.

［3］Long H，Tan Q，Luo Q，et al. Thoracoscopic surgery versus thoracotomy for lung cancer：short-term outcomes of a randomized trial.Annals of Thoracic Surgery，2018，105（2）：386-392.

［4］Wu YL，Lu S，Cheng Y，et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC：CheckMate 078 randomized phase Ⅲ clinical trial. J ThoracOncol，2019，14（5）：867-875.

［5］Gandara DR，Paul SM，Kowanetz M，et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.Nat Med，2018，24（9）：1441-1448.

［6］Wang Z，Zhao J，Wang G，et al.Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res，2018，78（22）：6486-6496.

［7］Han B，Li K，Wang Q，et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-amallcell lung cancer：The ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol，2018，4（11）：1569-1575.

［8］Lu S，Chang J，Liu X，et al. Randomized，double-blind，placebo-controlled，multicenter phase Ⅱstudy of fruquintinibafter two prior chemotherapy regimens in Chinese patients with advanced nonsquamousnon-smallcell lung cancer. J Clin Oncol，2018，36（12）：1207-1217.

［9］Wu YL，Zhang L，Kim DW，et al. Phase Ⅰb/Ⅱstudy of capmatinib（INC280）plus gefitinibafter failure of epidermal growth factor receptor（EGFR）inhibitor therapy in patients with EGFR-mutated，MET factordysregulatednon-small-cell lung cancer. J Clin Oncol，2018，36（31）：3101-3109.

［10］Wang Z，Cheng Y，An T，et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma.Lancet Respir Med，2018，6（9）：681-690.

［11］Wu YL，Yang JC1，Kim DW1. Phase Ⅱstudy of crizotinib in east asianpatients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol，2018，36（14）：1405-1411.

［12］Lu S，Chen Z，Hu C，et al. Nedaplatinplus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung-amulticenter，open-label，randomized，phase Ⅲtrial. J Thorac Oncol，2018，13（11）：1743-1749.

［13］Tian Y，Wang Z，Liu X，et al. Prediction of chemotherapeutic efficacy in non-small cell lung cancer by serum metabolomicprofiling. Clin Cancer Res，2018，24（9）：2100-2109.

［14］Xu Q，Zhou F，Liu H，et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol，2018，13（9）：1383-1392.

［15］Chen D，Song X，Wang H，et al. Previous radiotherapy increases the ffficacy of IL-2 in malignant pleural effusion：potential evidence of a radio-memory effect？Frontiers in immunology，2018，9：2916.

［16］Mok TS，Wu YL，Thongprasert S，et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med，2009，361（10）：947-957.

［17］Zhou C，Wu YL，Chen G，et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer（OPTIMAL，CTONG-0802）：a multicentre，open-label，randomised，phase 3 study.Lancet Oncol，2011，12（8）：735-742.

［18］Wu YL，Zhou C，Hu CP，et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations（LUX-Lung 6）：an open-label，randomised phase 3 trial.Lancet Oncol，2014，15（2）：213-222.

［19］Rosell R，Carcereny E，Gervais R，et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer（EURTAC）：a multicentre，open-label，randomised phase 3 trial. Lancet Oncol，2012，13（3）：239-246.

［20］Camidge DR，Pao W，Sequist LV. Acquired resistance to TKIs in solid tumours：learning from lung cancer.Nature reviews. Clin Oncol，2014，11（8）：473-481.

［21］Yang JJ，Chen HJ，Yan HH，et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung cancer（Amsterdam，Netherlands），2013，79（1）：33-39.

［22］Weickhardt AJ，Scheier B，Burke J M，et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol，2012，7（12）：1807-1814.

［23］Wong A C，Watson S P，Pitroda S P，et al. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy（SBRT）. Cancer，2016，122（14）：2242-2250.

［24］Gomez DR，Blumenschein GRJr，Lee JJ，et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy：a multicentre，randomised，controlled，phase 2 study. Lancet Oncol，2016，17（12）：1672-1682.

［25］Juan O，Popat S. Ablative therapy for oligometastaticnon-small cell lung cancer. Clinical lung cancer，2017，18（6）：595-606.

［26］Kwint M，Walraven I，Burgers S，et al. Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases. Lung cancer（Amsterdam，Netherlands），2017，112：134-139.

［27］Ashworth A B，Senan S，Palma D A，et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clinical lung cancer，2014，15（5）：346-355.

［28］Weichselbaum RR，Liang H，Deng L，et al. Radiotherapy and immunotherapy：a beneficial liaison？Nat Rev Clin Oncol，2017，14：365-379.

［29］Wersäll PJ，Blomgren H，Pisa P，et al.Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol，2006，45：493-497.

［30］Herrera FG，Bourhis J，Coukos G.Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin，2017，67：65-85.

［31］Mole RH. Whole body irradiation；radiobiology or medicine？Br J Radiol，1953，26：234-241.

［32］Ng J，Dai T. Radiation therapy and the abscopal effect：a concept comes of age. Ann Transl Med，2016，4：118.

［33］Levy A，Chargari C，Marabelle A，et al. Can immunostimulatory agents enhance the abscopal effect of radiotherapy？Eur J Cancer，2016，62：36-43.